Non-interventional study of the effectiveness and safety of Jardiance in patients with heart failure (HF) of reduced ejection fraction (HFrEF) compared to guideline-recommended non- SGLT2i therapy regimens in China: A sub-study of the postmarketing study of Jardiance among patients with heart failure in China

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/106701
• EU PAS number:
  EUPAS106700
• Study ID:
  106701
• Official title and acronym:
  Non-interventional study of the effectiveness and safety of Jardiance in patients with heart failure (HF) of reduced ejection fraction (HFrEF) compared to guideline-recommended non- SGLT2i therapy regimens in China: A sub-study of the postmarketing study of Jardiance among patients with heart failure in China
• DARWIN EU® study:
  No
• Study countries:
  China
• Study status:
  Planned

Research institutions and networks

Institutions

Heart Failure Medical Union of the National Center for Cardiovascular Diseases (HFMU-NCCD)

Study timelines

Date when funding contract was signed

Planned: 30/11/2023

Study start date

Planned: 30/06/2025

Date of final study report

Planned: 01/03/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable